Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression (original) (raw)
Houghton, A.N. Cancer antigens: immune recognition of self and altered self. J. Exp. Med.180, 1–4 (1994). ArticlePubMedCAS Google Scholar
Hellstrom, K.E., Hellstrom, I. & Chen, L. Can co-stimulated tumor immunity be therapeutically efficacious? Immunol. Rev.145, 123–145 (1995). ArticlePubMedCAS Google Scholar
Pardoll, D.M. Paracrine Cytokine Adjuvants in Cancer Immunotherapy Ann. Rev. Immunol.13, 399–415 (1995). ArticleCAS Google Scholar
Forni, G. et al. Molecular approaches to cancer immunotherapy Cytokin. Mol. Ther.1, 225–248 (1995). CAS Google Scholar
Vile, R.G. & Chong, H. Immunotherapy: Combinatorial molecular immunotherapy - a synthesis and suggestions. Can. Metast. Rev.15, 351–364 (1996). ArticleCAS Google Scholar
Cayeux, S., Richter, G., Noffz, G., Dorken, B. & Blankenstein, T. Influence of gene-modified (IL-7, IL-4 and B7) tumor cell cvaccines on tumor antigen presentation. J. Immunol.158, 2834–2841 (1997). PubMedCAS Google Scholar
Cavallo, F. et al. Protective and curative potential of vaccination with interleukin-2-gene transfected cells from a spontaneous mouse mammary adenocarcinoma. Cancer Res.51, 5067–5070 (1993). Google Scholar
Freeman, S.M., Ramesh, R. & Marrogi, A.J. Immune system in suicide gene therapy. Lancet349, 2–3 (1997). ArticlePubMedCAS Google Scholar
Huang, A.Y.C., Bruce, A.T., Pardoll, D.M. & Levitsky, H.I. In vivo cross-priming of MHC Class l-restricted antigens requires a TAP transporter. Immunity4, 349–355 (1996). ArticlePubMedCAS Google Scholar
Dranoff, G. et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte macrophage colony stimulating factor stimulates potent, specific, and long lasting anti-tumor immunity. Proc. Not. Acad. Sci. USA90, 3539–354. (1993). ArticleCAS Google Scholar
Suto, R. & Srivastava, P.K. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science269, 1585–1588 (1995). ArticlePubMedCAS Google Scholar
Tamura, Y., Peng, P., Liu, K., Daou, M. & Srivastava, P.K. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science278, 117–120 (1997). ArticlePubMedCAS Google Scholar
Barba, D., Hardin, J., Sadelain, M. & Gage, F.H. Development of anti tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc. Nat. Acad. Sci. USA91, 4348–4352 (1994). ArticlePubMedCASPubMed Central Google Scholar
Caruso, M. et al. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc. Nat. Acad. Sci. USA90, 7024–7028 (1993). ArticlePubMedCASPubMed Central Google Scholar
Vile, R.G., Nelson, J.A., Castleden, S., Chong, H. & Hart, I.R. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Research54, 6228–6234 (1994). PubMedCAS Google Scholar
Vile, R.G. et al. Generation of an anti-tumor immune response in a non-immunogenic tumor: HSVtk-killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoral cytokine expression. Intl. J. Cancer71, 267–274 (1997). ArticleCAS Google Scholar
Castleden, S.A. et al. A family of bicistronic vectors to enhance both local and systemic anti tumor effects of HSVtk or cytokine expression in a murine melanoma model. Hum. Cene Ther.8, 2087–2102 (1997). ArticleCAS Google Scholar
Consalvo, M. et al. 5-fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory. J. Immun.154, 5302–5312 (1995). PubMedCAS Google Scholar
Mullen, C.A., Coale, M.M., Lowe, R. & Blaese, R.M. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. Can. Res.54, 1503–1506 (1994). CAS Google Scholar
Colombo, M.P., Modesti, A., Parmiani, G. & Forni, G. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Can. Res.52, 4853–485 (1992). CAS Google Scholar
Huang, A.Y.C. et al. Role of bone marrow derived cells in presenting MHC Class I-restricted tumor antigens. Science264, 961–965 (1994). PubMedCAS Google Scholar
Maass, G. et al. Priming of tumor specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: Three consecutive stages may be required for successful tumor vaccination. Proc. Nat. Acad. Sci. USA92, 5540–5544 (1995). ArticlePubMedCASPubMed Central Google Scholar
Fuchs, E.J. & Matzinger, P. Is cancer dangerous to the immune system? Sem. Immunol.8, 271–280 (1996). ArticleCAS Google Scholar
Matzinger, P. Tolerance, danger and the extended family. Annual Review of Immunol.12, 991–1045 (1994). ArticleCAS Google Scholar
Speiser, D.E. et al. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: Implications for immunotherapy. J. Exp. Med.186, 645–653 (1997). ArticlePubMedPubMed CentralCAS Google Scholar
Castleden, S.A. Combination gene therapies for the immunotherapy of cancer. PhD Thesis, University of London. (1997).
Vile, R.G., & Hart, I.R. Use of tissue-specific expression of the Herpes Simplex Virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Can. Res.53, 3860–3864 (1993). CAS Google Scholar
Wyllie, A.H. Apoptosis (The 1992 Frank Rose Memorial Lecture) B. J. Can.67, 205–208 (1993). ArticleCAS Google Scholar
Columbano, A. Cell death: current difficulties in discriminating apoptosis from necrosis in the context of pathological processes in vivo. J. Cell. Biochem.58, 181–190 (1995). ArticlePubMedCAS Google Scholar
Plettenberg, A. et al. Human melanocytes and melanoma cells constitutively express the Bcl-22 protooncogene in situ and in cell culture. Am. J. Path.146, 651–659 (1995). PubMedCASPubMed Central Google Scholar
Hunt, C. & Calderwood, S. Characterisation and sequence of a mouse hsp70 gene and its expression in mouse cell lines. Gene87, 199–204 (1990). ArticlePubMedCAS Google Scholar
Perry, M.D., Aujame, L., Shtang, S. & Moran, L. Structure and expression of an in-ducible HSP70-encoding gene from Mus musculus. Gene146, 273–278 (1994). ArticlePubMedCAS Google Scholar
Freeman, S.M. et al. The “bystander effect”: tumor regression when a fraction of the tumor mass is genetically modified. Can. Res.53, 5274–5283 (1993). CAS Google Scholar
Kaneko, Y. & Tsukamoto, A. Gene therapy of hepatoma: bystander effects and non-apoptotic cell death induced by thymidine kinase and ganciclovir Can. Let.96, 105–110 (1995). ArticleCAS Google Scholar
Udono, H., Levey, D.L. & Srivastava, P.K. Cellular requirements for tumor-specific immunity elicited by heat shock proteins: tumor rejection antigen gp96 primes CD8+ T cells in vivo. Proc. Nat. Acad. Sci. USA91, 3077–3081 (1994). ArticlePubMedCASPubMed Central Google Scholar
Li, Z. Priming of T cells by heat shock protein-peptide complexes as the basis of tumor vaccines. Sem. Immunol.9, 315–322 (1997). ArticleCAS Google Scholar
Wei, Y.-q. et al. Induction of autologous tumor killing by heat treatment of fresh human tumor cells: Involvement of γδ T cells and heat shock protein 70. Can. Res.56, 1104–1110 (1996). CAS Google Scholar
Multhoff, G. et al. Heat shock protein 72 on tumor cells: A recognition structure for Natural Killer cells. J. Immunol.158, 4341–4350 (1997). PubMedCAS Google Scholar
Lukacs, K.V., Lowrie, D.B., Stokes, R.W. & Colston, M.J. Tumor cells transfected with a bacterial heat-shock gene lose tumorigenicity and induce protection against tumors. J. Exp. Med.178, 343–3 (1993). ArticlePubMedCAS Google Scholar
Lukacs, K.V., Nakakes, A., Atkins, C.J., Lowrie, D.B. & Colston, M.J. In vivo gene therapy of malignant tumors with heat shock protein-65 gene. Gene Ther.4, 346–350 (1997). ArticlePubMedCAS Google Scholar